Format

Send to

Choose Destination
Curr Opin Pulm Med. 2013 Sep;19(5):516-23. doi: 10.1097/MCP.0b013e3283642ad0.

Nonsteroidal therapy of sarcoidosis.

Author information

1
Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany.

Abstract

PURPOSE OF REVIEW:

None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years.

RECENT FINDINGS:

Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients.

SUMMARY:

Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.

PMID:
23884295
PMCID:
PMC4134017
DOI:
10.1097/MCP.0b013e3283642ad0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center